At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 169 enrolled
Drug / intervention
romiplostimbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
In Brief
A Phase 4 clinical trial evaluating romiplostim for Thrombocytopenia and Idiopathic Thrombocytopenic Purpura. Completed, enrolled 169 participants.
Detailed Summary
The purpose of this study is to evaluate changes in bone marrow morphology (structure) after long-term exposure to romiplostim.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartAug 2009
Primary CompletionJan 2014
Study CompletionJan 2014
TodayJul 2026
First PostedMay 22, 2009
Enrollment StartAug 11, 2009
Primary CompletionJan 9, 2014
Study CompletionJan 14, 2014
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 17.1 years ago
Interventions
romiplostimbiological
Romiplostim administered by subcutaneous injection